Medicare Coverage-In-Clinical-Trials Policy For Alzheimer’s Drugs Could Stifle Access For Years
Executive Summary
Proposed Medicare national coverage policy would delay access to Alzheimer’s drugs for too long and the government should instead cover the drugs under specific conditions until research already underway comes in, Global Alzheimer’s Platform Foundation president John Dwyer argues.
You may also be interested in...
A New Patient Voice In The Medicare/Alzheimer’s Drug Coverage Debate
Individuals with Down syndrome are particularly vulnerable to the disease yet would be excluded from participating in clinical trials described in the draft Medicare coverage policy for Alzheimer’s drugs.
Medicare And Alzheimer's Drugs: Grassroots Campaign Opposing Coverage Aims To ‘Take On Big Pharma’
Nearly 5,000 comments from individuals on CMS’ proposal to restrict coverage of Alzheimer’s drugs argue that Aduhelm should never have been approved and should not be covered. The outpouring is surprising in light of expectations there would be a flood of patient comments urging broader coverage.
CMS Needs Regulatory Science, Chief Scientist To Coordinate With US FDA, Former Official Says
Sean Tunis embraces a bigger decision-making role for CMS in product access, while FDA Commissioner nominee Robert Califf also calls for smoother FDA-CMS hand-offs, and CBER Director Peter Marks wants a quicker FDA-CDC approval and deployment process.